RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model. Issue 2 (15th November 2019)

• Record Type: Journal Article
• Authors: Thomas‐Jardin, Shayna E.; Dahl, Haley; Kanchwala, Mohammed S.; Ha, Freedom; Jacob, Joan; Soundharrajan, Reshma; Bautista, Monica; Nawas, Afshan F.; Robichaux, Dexter; Mistry, Ragini; Anunobi, Vanessa; Xing, Chao; Delk, Nikki A.
• Is Part Of: Prostate. Volume 80:Issue 2(2020)
• Page Start: 133
• Page End: 145
• Publication Date: 2019-11-15
• Subjects: androgen receptor -- interleukin‐1 -- prostate cancer -- RELA; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23925
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Background: The androgen receptor (AR) nuclear transcription factor is a therapeutic target for prostate cancer (PCa). Unfortunately, patients can develop resistance to AR‐targeted therapies and progress to lethal disease, underscoring the importance of understanding the molecular mechanisms that underlie treatment resistance. Inflammation is implicated in PCa initiation and progression and we have previously reported that the inflammatory cytokine, interleukin‐1 (IL‐1), represses AR messenger RNA (mRNA) levels and activity in AR‐positive (AR + ) PCa cell lines concomitant with the upregulation of prosurvival biomolecules. Thus, we contend that IL‐1 can select for AR‐independent, treatment‐resistant PCa cells. Methods: To begin to explore how IL‐1 signaling leads to the repression of AR mRNA levels, we performed comprehensive pathway analysis on our RNA sequencing data from IL‐1‐treated LNCaP PCa cells. Our pathway analysis predicted nuclear factor kappa B (NF‐κB) p65 subunit (RELA), a canonical IL‐1 signal transducer, to be significantly active and potentially regulate many genes, including AR . We used small interfering RNA (siRNA) to silence the NF‐κB family of transcription factor subunits, RELA, RELB, c‐REL, NFKB1, or NFKB2, in IL‐1‐treated LNCaP, C4‐2, and C4‐2B PCa cell lines. C4‐2 and C4‐2B cell lines are castration‐resistant LNCaP sublines and represent progression toward metastatic PCa disease, and we have previously shown that IL‐1 represses AR mRNA levels in C4‐2 and C4‐2B cells. Results: siRNA revealed that RELA alone is sufficient to mediate IL‐1 repression of AR mRNA and AR activity. Intriguingly, while LNCaP cells are more sensitive to IL‐1‐mediated repression of AR than C4‐2 and C4‐2B cells, RELA siRNA led to a more striking derepression of AR mRNA levels and AR activity in C4‐2 and C4‐2B cells than in LNCaP cells. Conclusions: These data indicate that there are RELA‐independent mechanisms that regulate IL‐1‐mediated AR repression in LNCaP cells and suggest that the switch to RELA‐dependent IL‐1 repression of AR in C4‐2 and C4‐2B cells reflects changes in epigenetic and transcriptional programs that evolve during PCa disease progression.